More News! 16 Apr 2018
Epitopes Come to the Rescue for One of the Most Common Autoimmune Diseases
The British-Belgian biotech Apitope has obtained positive Phase I results for its first-in-class treatment for Graves' disease, one of the…
Apitope
- Latest Posts
News and Trends 1 Nov 2017
Belgian Biotech Launches IPO, Readying Itself to Fight Multiple Sclerosis
Apitope develops highly specific peptide therapeutics for multiple sclerosis and other autoimmune diseases, and will now launch an IPO on…
In Depth 24 May 2017
What Happens when the Immune System Attacks Life-Saving Drugs?
Immunogenicity has been largely disregarded despite its huge impact on the performance of biological drugs. What is it and how…
News and Trends 21 Feb 2017
A New Peptide Vaccine for Multiple Sclerosis Succeeds in Phase IIa
Apitope is developing therapeutic peptides to induce suppression of autoimmune responses towards self-antigens. Their recent phase IIa trial has revealed…
ADVERTISEMENT
News and Trends 30 Sep 2015
Apitope relocates to Wales after €12M series B financing round
Now, as we've recently discussed here at Labiotech, there doesn't appear to be many Welsh biotechs...however, this is all about…
